Standout Papers
Citation Impact
Citing Papers
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies
2008 Standout
Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir Resistance
2010 ScienceNobel
Mapping the Antigenic and Genetic Evolution of Influenza Virus
2004 StandoutScience
Cell entry mechanisms of SARS-CoV-2
2020 Standout
Characterization of a canine homolog of hepatitis C virus
2011 StandoutNobel
HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype
2007 StandoutNobel
Evidence for a functional RNA element in the hepatitis C virus core gene
2007 StandoutNobel
Memory CD8 + T Cells Are Required for Protection from Persistent Hepatitis C Virus Infection
2003 StandoutNobel
Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover
2007
Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1)
2013 StandoutNobel
The Yellow Fever Virus Vaccine Induces a Broad and Polyfunctional Human Memory CD8+ T Cell Response
2009 StandoutNobel
HIV Envelope Suppresses CD4+ T Cell Activation Independent of T Regulatory Cells
2008 StandoutNobel
Expansion and Function of CD8+ T Cells Expressing Ly49 Inhibitory Receptors Specific for MHC Class I Molecules
2004 StandoutNobel
An Expanded View of Complex Traits: From Polygenic to Omnigenic
2017 Standout
Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients
2006
CD8+ cytotoxic T lymphocyte responses to lentiviruses and herpesviruses
2001
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
2009 StandoutNature
Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial
2012
Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27–restricted human immune response
2009
Cellular senescence: when bad things happen to good cells
2007 Standout
Unravelling hepatitis C virus replication from genome to function
2005 StandoutNatureNobel
Allopurinol hypersensitivity: investigating the cause and minimizing the risk
2015
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
2006
Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines
2023 StandoutNobel
The Outcome of Hepatitis C Virus Infection Is Predicted by Escape Mutations in Epitopes Targeted by Cytotoxic T Lymphocytes
2001 StandoutNobel
Genetics of susceptibitlity to human infectious disease
2001
Management of Hepatic Complications in HIV‐Infected Persons
2008
First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir
2009
Cellular immune responses to HIV
2001 Nature
Prolonged Activation of Virus-Specific CD8+T Cells after Acute B19 Infection
2005
Lack of Epstein-Barr virus- and HIV-specific CD27− CD8+ T cells is associated with progression to viral disease in HIV-infection
2002
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model
2008 Standout
CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained
2000
Drug-Induced Hypersensitivity Syndrome
2009
Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores
2007
Functional Impairment of CD8+ T Cells by Regulatory T Cells during Persistent Retroviral Infection
2004 StandoutNobel
Prospects for a vaccine against the hepatitis C virus
2005 StandoutNatureNobel
Treatment for Adult HIV Infection
2006
Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution
2006
Exploiting dendritic cells to improve vaccine efficacy
2002 StandoutNobel
MX2 is an interferon-induced inhibitor of HIV-1 infection
2013 StandoutNatureNobel
Gout
2016 Standout
Myocarditis
2011 Standout
In vitro senescence of immune cells
2003
Comprehensive Analyses of a Unique HIV-1-Infected Nonprogressor Reveal a Complex Association of Immunobiological Mechanisms in the Context of Replication-Incompetent Infection
2002
The end of AIDS: HIV infection as a chronic disease
2013 Standout
Management of the metabolic effects of HIV and HIV drugs
2011
Pharmacokinetics, Safety, and Efficacy of Tipranavir Boosted With Ritonavir Alone or in Combination With Other Boosted Protease Inhibitors as Part of Optimized Combination Antiretroviral Therapy in Highly Treatment-Experienced Patients (BI Study 1182.51)
2008
Tipranavir
2008
Computational design of trimeric influenza-neutralizing proteins targeting the hemagglutinin receptor binding site
2017 StandoutNobel
Tipranavir: a novel protease inhibitor for HIV therapy
2009
The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?
2002
Initiating Therapy: When to Start, What to Use
2008
Leprosy
2004 Standout
Antiretroviral Drug Resistance Testing in Adult HIV‐1 Infection: 2008 Recommendations of an International AIDS Society–USA Panel
2008
Treatment for Adult HIV Infection
2004
Extreme Genetic Fragility of the HIV-1 Capsid
2013
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
2008 Standout
Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey
2007
Advances in understanding immunologic control of HIV infection
2004
High Sensitivity of Human Leukocyte Antigen–B*5701 as a Marker for Immunologically Confirmed Abacavir Hypersensitivity in White and Black Patients
2008
Infection in Solid-Organ Transplant Recipients
2007 Standout
Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS
2005 StandoutNobel
Antiretroviral Treatment of Adult HIV Infection
2012 Standout
Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS
2002
Common Genetic Variation and Human Traits
2009
Genetic heterologous prime–boost vaccination strategies for improved systemic and mucosal immunity
2009
Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees
2004 StandoutNobel
HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors
2002
Mathematical modeling of primary hepatitis C infection: Noncytolytic clearance and early blockage of virion production
2005 StandoutNobel
Exploiting dendritic cells to improve vaccine efficacy
2002 StandoutNobel
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates
2011 StandoutNobel
Flying Under the Radar: The Immunobiology of Hepatitis C
2006 StandoutNobel
Exploiting dendritic cells to improve vaccine efficacy
2002 StandoutNobel
Mutational escape from CD8+ T cell immunity
2005
DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8 + T cells in a spectrum of human MHC I haplotypes
2007 StandoutNobel
Exploring the Geometry of Treatment Networks
2008
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Cellular immune responses against hepatitis C virus: the evidence base 2002
2002
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
2015 Standout
Studying Hepatitis C Virus: Making the Best of a Bad Virus
2007 StandoutNobel
Genetic diversity and evolution of hepatitis C virus – 15 years on
2004
Maintenance of viral suppression in HIV-1–infected HLA-B*57+ elite suppressors despite CTL escape mutations
2006
Kinetics of CD4+and CD8+Memory T-Cell Responses during Hepatitis C Virus Rechallenge of Previously Recovered Chimpanzees
2003 StandoutNobel
Population dynamics of rapid fixation in cytotoxic T lymphocyte escape mutants of influenza A
2003
Functional Heterogeneity of Cytokines and Cytolytic Effector Molecules in Human CD8+ T Lymphocytes
2001
A Common Dominant TLR5 Stop Codon Polymorphism Abolishes Flagellin Signaling and Is Associated with Susceptibility to Legionnaires' Disease
2003 StandoutNobel
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
2015 Standout
Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS
2005 StandoutNobel
Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals
2007 StandoutNobel
Cutting Edge: Increased NK Cell Activity in HIV-1-Exposed but Uninfected Vietnamese Intravascular Drug Users
2003 StandoutNobel
HIV VACCINES
2005
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients
2008
Determinants of Human Immunodeficiency Virus Type 1 Escape from the Primary CD8+ Cytotoxic T Lymphocyte Response
2004
Ex vivoanalysis of phenotype and TCR usage in relation to CD45 isoform expression on cytomegalovirus-specific CD8+ T lymphocytes
2001
Works of Cassy Workman being referenced
Correlates of Antiviral Immune Restoration in Acute and Chronic HIV Type 1 Infection: Sustained Viral Suppression and Normalization of T Cell Subsets
2002
High Frequency of Cytomegalovirus‐Specific Cytotoxic T‐Effector Cells in HLA‐A*0201–Positive Subjects during Multiple Viral Coinfections
2000
Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults
2008
Influence of IFNγ Co-Expression on the Safety and Antiviral Efficacy of Recombinant Fowlpox Virus HIV Therapeutic Vaccines Following Interruption of Antiretroviral Therapy
2007
HLA-B*5701 Screening for Hypersensitivity to Abacavir
2008 Standout
Efficacy of the Protease Inhibitors Tipranavir plus Ritonavir in Treatment-Experienced Patients: 24-Week Analysis from the RESIST-1 Trial
2006
Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir
2004
A Randomised Trial Comparing Genotypic and Virtual Phenotypic Interpretation of HIV Drug Resistance: The CREST Study
2006
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis
2009
No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial
2004
Clustered Mutations in HIV-1 Gag Are Consistently Required for Escape from Hla-B27–Restricted Cytotoxic T Lymphocyte Responses
2001